Market Research Logo

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2025

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2025

Summary

Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection. In CLL, the DNA of a B cell is damaged so that it cannot fight infection, but instead, it grows out of control and affects the healthy blood cells that can fight infection (NCI, 2016). CLL is closely related to small lymphocytic lymphoma (SLL), a type of non-Hodgkin's lymphoma that presents primarily in the lymph nodes.

In the 7MM, epidemiologists forecast an increase in the diagnosed incident cases of CLL from 40,631 diagnosed incident cases in 2015 to 49,643 diagnosed incident cases in 2025, with an annual growth rate (AGR) of 2.22% during the forecast period. The US will have the highest number of diagnosed incident cases of CLL among the 7MM throughout the forecast period, while Spain will have the lowest.

The report EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2025 provides an overview of the risk factors, comorbidities, and the global and historical trends for CLL in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada). The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CLL segmented by age (for ages 18 years and older) and sex. Additionally, the CLL diagnosed incident cases are segmented by Rai and Binet stage at diagnosis, symptom status (symptomatic vs. asymptomatic), and immunoglobulin heavy chain variable (IGHV) region gene mutation status (mutated vs. unmutated) for the 7MM.

Scope

  • The Chronic lymphocytic leukemia (CLL) EpiCast Report provides an overview of the risk factors and global trends of CLLin the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CLL and five-year diagnosed prevalent cases of CLL. Incident cases are segmented by age, sex, Rai and Binet stage at diagnosis, symptom status (symptomatic vs. asymptomatic), and immunoglobulin heavy chain variable (IGHV) region gene mutation status (mutated vs. unmutated) for the 7MM. The diagnosed incident cases of CLL with the mutations 17p deletion, 11q deletion, and TP53 are also provided in the report.
  • The CLL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The CLL EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global CLL market.
  • Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CLL therapeutics in each of the markets covered.
  • Understand magnitude of CLL population by two staging systems.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Diagnosed Incident Cases
3.4.4 Diagnosed Incident Cases by Stage at Diagnosis (Rai Staging)
3.4.5 Diagnosed Incident Cases by Stage at Diagnosis (Binet Staging)
3.4.6 Diagnosed Incident Cases by Disease Symptom Status
3.4.7 Mutations (17p deletion, 11q Deletion, and TP53) Among the Diagnosed Incident Cases of CLL
3.4.8 IGHV Mutation Among Diagnosed Incident Cases of CLL
3.4.9 Five-Year Diagnosed Prevalent Cases of CLL
3.5 Epidemiological Forecast for CLL (2015-2025)
3.5.1 Diagnosed Incident Cases of CLL
3.5.2 Age-Specific Diagnosed Incident Cases of CLL
3.5.3 Sex-Specific Diagnosed Incident Cases of CLL
3.5.4 Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging)
3.5.5 Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging)
3.5.6 Diagnosed Incident Cases of CLL by Disease Symptom Status
3.5.7 Diagnosed Incident Cases of CLL with 17p Deletion
3.5.8 Diagnosed Incident Cases of CLL with 11q Deletion
3.5.9 Diagnosed Incident Cases of CLL with TP53 Mutation
3.5.10 Diagnosed Incident Cases of CLL by IGHV Mutation Status
3.5.11 Five-Year Diagnosed Prevalent Cases of CLL
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer
1.1 List of Tables
Table 1: CLL Clinical Stages
Table 2: Risk Factors and Comorbidities for CLL
Table 3: 7MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, Selected Years 2015-2025.
Table 4: 7MM, Five-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ≥18 Years, Selected Years 2015-2025
1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, 2015 and 2025
Figure 2: 7MM, Five-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ≥18 Years , 2015 and 2025
Figure 3: 7MM, CLL Age-Standardized Diagnosed Incidence (Cases per 100,000 Population), Men, Ages ≥18 Years, 2005 to 2025
Figure 4: 7MM, CLL Age-Standardized Diagnosed Incidence (Cases per 100,000 Population), Women, Ages ≥18 Years, 2005 to 2025
Figure 5: 7MM, Sources Used, Diagnosed Incident Cases of CLL
Figure 6: 7MM, Sources Used, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging)
Figure 7: 7MM, Sources Used, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging)
Figure 8: 7MM, Sources Used, 17p Deletion Among the Diagnosed Incident Cases of CLL
Figure 9: 7MM, Sources Used, 11q Deletion Among the Diagnosed Incident Cases of CLL
Figure 10: 7MM, Sources Used, TP53 Mutation Among the Diagnosed Incident Cases of CLL
Figure 11: 7MM, Sources Used, Diagnosed Incident Cases of CLL by IGHV Mutation Status
Figure 12: 7MM, Sources Used and Not Used, Five-Year Diagnosed Prevalent Cases of CLL
Figure 13: 7MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, 2015
Figure 14: 7MM, Sex-Specific Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, 2015
Figure 15: 7MM, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging), Both Sexes, Ages ≥18 Years, 2015
Figure 16: 7MM, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging), Both Sexes, Ages ≥18 Years, 2015
Figure 17: 7MM, Diagnosed Incident Cases of CLL by Disease Symptom Status, Both Sexes, Ages ≥18 Years, 2015
Figure 18: 7MM, Diagnosed Incident Cases of CLL with 17p Deletion, Both Sexes, Ages ≥18 Years, 2015
Figure 19: 7MM, Diagnosed Incident Cases of CLL with 11q Deletion, Both Sexes, Ages ≥18 Years, 2015
Figure 20: 7MM, Diagnosed Incident Cases of CLL with TP53 Mutation, Both Sexes, Ages ≥18 Years, 2015
Figure 21: 7MM, Diagnosed Incident Cases of CLL by IGHV Mutational Status, Both Sexes, Ages ≥18 Years, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report